Purpose of this Study
We are doing this study to find out if an experimental drug called MK-2870 (the study drug) is an option for patients with endometrial cancer. We want to know how well it works compared to standard chemotherapy.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with endometrial carcinoma or carcinosarcoma
- Have received previous treatment with platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy (given either together or separately)
- Are not pregnant or breastfeeding
Age Range
18-110
Sex/Genders
Female (cisgender)
Non-binary or gender fluid
Transgender male
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will get a random assignment (like a coin flip) to either take the study drug or a combination of doxorubicin and paclitaxel (the standard chemotherapy regimen).
- If you are assigned the study drug, you will get a dose of it every 2 weeks.
- If you are assigned to get standard chemotherapy, you will get a dose of doxorubicin once every 3 weeks. You will also get paclitaxel once per week for 3 out of 4 weeks.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to
Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of
Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior
Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-
3095)
Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of
Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior
Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-
3095)
Principal Investigator
Angeles
Secord
Protocol Number
PRO00114641
NCT ID
NCT06132958
Phase
III
Enrollment Status
Open to Enrollment